EPEsther Paran

Esther Paran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Esther Paran has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Tomato Nutrient Complex on Blood Pressure: A Double Blind, Randomized Dose–Response Study

    by Talia Wolak, Yoav Sharoni, Joseph Levy, Karin Linnewiel-Hermoni, David Stepensky, Esther Paran

    Oxidative stress is implicated in the pathogenesis of essential hypertension, a risk factor for cardiovascular morbidity and mortality. Tomato carotenoids such as lycopene and the colorless carotenoids phytoene and phytofluene induce the antioxidant defense mechanism. This double-blind, randomized, placebo-controlled study aimed to find effective doses of Tomato Nutrient Complex (TNC) to maintain normal blood pressure in untreated hypertensive individuals. The effect of TNC treatment (5, 15 and 30 mg lycopene) was compared with 15 mg of synthetic lycopene and a placebo over eight weeks. Results indicate that only TNC treatment standardized for 15 or 30 mg of lycopene was associated with significant reductions in mean systolic blood pressure (SBP). Treatment with the lower dose standardized for 5 mg of lycopene or treatment with 15 mg of synthetic lycopene as a standalone had no significant effect. To test carotenoid bioavailability, volunteers were treated for four weeks with TNC providing 2, 5 or 15 mg lycopene. The increase in blood levels of lycopene, phytoene, and phytofluene was dose dependent. Results suggest that only carotenoid levels achieved by the TNC dose of 15 mg lycopene or higher correlate to a beneficial effect on SBP in hypertensive subjects while lower doses and lycopene alone do not.


  • Tomato extract and the carotenoids lycopene and lutein improve endothelial function and attenuate inflammatory NF-κB signaling in endothelial cells

    by Anna Armoza, Yulia Haim, Asher Basiri, Talya Wolak, Esther Paran

    Objectives: In our previous research the antihypertensive properties of lycopene-containing tomato oleoresin have been revealed. The present study was aimed to assess if oleoresin interferes in the inflammatory signalling in endothelial cells, imitating reduction of inflammatory processes in the vessel wall and in this way to propose the mechanism for the reduction of blood pressure by oleoresin. Methods and results: A wide number of functional and inflammatory markers were investigated in two cultured endothelial cell models [EA.hy926 and human umbilical vein endothelial cell (HUVEC)], exposed to oleoresin and carotenoids lycopene and lutein. All the carotenoids significantly improved basic endothelial function as measured by increased nitric oxide and decreased endothelin (ET-1) release. They were effective in attenuation of inflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling: decrease of tumour necrosis factor-alpha (TNF-α)-induced leukocytes adhesion, expression of adhesion molecules inter-cellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), and nuclear translocation of NF-κB components as well as some revert of inhibitor of kappa B (IκB) ubiquitination. In addition, the carotenoids were able to inhibit NF-κB activation in transfected endothelial cells. When combined with lutein, oleoresin exerted synergistic effect on preclusion of leukocytes adhesion. Conclusions: Prevention of over-expression of adhesion molecules through inhibition of NF-κB signalling may be one of the main mechanisms driving carotenoids to attenuate inflammatory leukocyte adhesion to endothelium. This is the first profound study on the mechanisms involved in the positive action of natural tomato products in endothelial cells.


    • 1 October 2011
      • Vol. 13  (10) , 619-24

    Does percutaneous transluminal renal artery angioplasty improve blood pressure control and renal function in patients with atherosclerotic renal artery stenosis?

    by Talya Wolak, Ana Belkin, Victor Ginsburg, George Greenberg, Olga Mayzler, Arkady Bolotin, Esther Paran, Gabriel Szendro

    Percutaneous angioplasty (PTA) and stenting is an established procedure for the treatment of hypertension caused by atherosclerotic renal artery stenosis. However recently, the decision whether or notto perform this procedure has raised considerable debate. To examine the association between the basic clinical and radiological characteristics of candidates for renal artery PTA and the clinical outcome of the procedure in terms of improvement of blood pressure control and renal function. We conducted a retrospective cohort study of all patients who underwent percutaneous transluminal renal artery angioplasty (PTRA) and stent implantation in a tertiary medical center during the period 2000-2007. The clinical and radiological data were extracted from the medical file of each patient. Blood pressure measurements and creatinine level were recorded before the procedure and 1 month, 6 months, 12 months and 18 months after PTRA. Thirty-two patients were included in the final statistical analysis. The mean age of the study population was 66.6 +/- 8.8 years old and 75% were men. There was a significant reduction in both systolic and diastolic blood pressure 1 month after the procedure: 160.5 +/- 24.7 vs. 141.8 +/- 23.6 mmHg and 83.8 +/- 12.9 vs. 68.8 +/- 11.8 mmHg respectively (P < 0.001). The reduction in blood pressure was constant throughout the follow-up period and was evident 18 months after the procedure: 160.5 +/- 24.7 vs. 135.0 +/- 35.1 mmHg and 83.8 +/- 12.9 vs. 71.3 +/- 16.5 mmHg respectively (P < 0.001). However, no improvement in renal function was observed at any time during the follow-up period. We could not demonstrate an association between clinical or radiological features and the clinical outcome after PTRA. Our findings show that PTRA can be considered an effective procedure for improving blood pressure control in patients with atherosclerotic renal artery stenosis (ARAS) and resistant hypertension. This research, together with previous studies, strengthens the knowledge that the decline in glomerular filtration rate seen in many patients with ARAS is non-reversible and is not improved by PTRA.


  • The Dynamics of Blood Pressure and Cognitive Functioning: Results From 6‐Year Follow‐Up of an Elderly Cohort

    by Ester Paran, Ofra Anson

    J Clin Hypertens (Greenwich). 2011;13:813–817. ©2011 Wiley Periodicals, Inc.The association between blood pressure (BP) and cognitive functioning in the elderly is still under debate. Theoretically, high BP could either prevent or enhance cognitive impairment. The authors assessed the changes that took place in BP and cognitive functioning over 6 years. A total of 318 noninstitutional elderly (81% of the survivors) were re‐evaluated. BP was measured and a cognitive test was performed. Elderly patients who had higher systolic BP (SBP) and scored lower on the Mini‐Mental State Examination (MMSE) at baseline were less likely to survive. At follow‐up, the proportion of patients with normal or normalized BP by treatment increased. Considerable changes in SBP were observed. Most cognitive functions declined during follow‐up; however, decline in SBP was associated with better verbal fluency and memory. Both an increase and a decline in SBP were associated with better MMSE scores. Changes in diastolic BP (DBP) were less evident and DBP was not related to cognitive functioning. The current study demonstrates the importance of studying the dynamics of both BP and cognition over time. It appears that transition from hypertension to normotension improves cognitive functions. Survival processes may restrict the evaluation of the BP‐cognition interaction over time.


  • Cognitive Function and Antihypertensive Treatment in the Elderly: A 6-Year Follow-up Study

    by Esther Paran, Ofra Anson, David T Lowenthal

    Both antihypertensive treatment and statins were proved to reduce mortality and morbidity from cardiovascular disease in the elderly. Yet their effect on cognitive functions of the elderly is unclear. In this study, 518 elderly were interviewed at their home six years ago. BP was measured and antihypertensive drug treatment and cognitive functions were evaluated. 318 of the original sample were re-examined (81% of the survivors). We evaluated the selective survival in relation to changes in BP, the specific drug usage and cognitive functioning. Beta blocker treatment increased the odds of survival but also the odds of decline in MMSE and memory scores. ACE-I treatment was also associated with decline in memory. Subjects treated with CCB had improved MMSE scores, memory, and performed better on tasks requiring concentration. Statins treatment in this study did not show any affect on cognitive functions. Although most subjects were treated by more than one antihypertensive drug, less than half were normalized at baseline and only one quarter at follow-up. Despite the low normalization rate, antihypertensive treatment regimen had been hardly changed during the six years follow-up. The use of statins, however, increased dramatically: from 6% at baseline to almost half at follow-up. According to our findings CCB emerges as the best option for reducing BP in elderly patients. It appeared to improve cognitive functions without hampering survival.


    • 1 March 2010
      • Vol. 149  (3) , 161-5, 194

    [Target organ damage in hyperaldosteronism versus essential hypertension--the Beer Sheba experience].

    by Talya Wolak, Inbal Hazkani, Michael Friger, Esther Paran

    Primary hyperaldosteronism (PAL) is the main cause for secondary hypertension. PAL also increases the risk for target organ damage. To evaluate the rate of target organ damage in PAL patients versus essential hypertension patients (EHT) and to compare the rate of target organ damage in PAL patients who had adrenal adenoma versus patients with no adrenal adenoma. The study population included patients from the outpatient hypertensive clinic at Soroka University Medical Center between the years 2000-2005. The diagnosis of PAL was performed according to standard protocol. A total of 49 patients were diagnosed with PAL. This group of patients was composed of 12 patients with adrenal adenoma and 37 patients with no adrenal adenoma. The PAL patients were compared to 40 EHT patients. PAL and EHT patients were similar in their age, gender and prevalence of diabetes mellitus. The initial blood pressure measurements were comparable between the two groups. There was significant reduction in blood pressure in PAL and EHT after initiation of appropriate treatment. However, the reduction in systolic blood pressure was higher in the PAL group. Generally, there was tendency for higher rates of target organ damage in the PAL group versus the EHT group. In the PAL patients with adrenal adenoma versus the group with no adrenal adenoma, a significant higher prevalence of brain involvement was observed. The diagnosis of PAL is essential in order to provide the appropriate treatment for blood pressure reduction and prevention of target organ damage.

  • Left Ventricular Geometric Abnormality Screening in Hypertensive Patients Using a Hand‐Carried Ultrasound Device

    by Galit Perez‐Avraham, Sergio L. Kobal, Ohad Etzion, Victor Novack, Talya Wolak, Noah Liel‐Cohen, Esther Paran

    J Clin Hypertens (Greenwich). 2010;12:181–186. ©2010 Wiley Periodicals, Inc.The authors assessed the validity of a hand‐carried cardiac ultrasound device operated by an internal medicine resident for left ventricular geometric abnormalities (LVGAs) in mild hypertensive patients. LVGAs were diagnosed when at least one of the following was present: left ventricular mass index exceeding 125 g/m2 and 110 g/m2 for men and women, respectively; intraventricular septum thickness ≥10 mm; posterior wall thickness ≥10 mm; and left ventricular end‐diastolic diameter ≥5.3 mm. For validation, a cardiologist performed standard echocardiography in all patients. A total of 85 patients completed both echocardiographic studies. LVGAs were diagnosed in 19 (22.4%) cases, 18 of which were confirmed by standard echocardiography. Standard echocardiography did not detect any case of LVGA among the hand‐carried cardiac ultrasonography LVGA‐negative patients. The sensitivity and specificity of the resident’s examination were 100% and 98.78%, respectively. Agreement between the two studies was 99% (κ 0.97, 95% confidence interval). Hand‐carried cardiac ultrasonography may be used as a screening tool for LVGA in hypertensive patients.


  • The Effects of Natural Antioxidants from Tomato Extract in Treated but Uncontrolled Hypertensive Patients

    by Esther Paran, Victor Novack, Yechiel Nir Engelhard, Inbal Hazan-Halevy

    To evaluate the effect of adding tomato extract to the treatment regime of moderate hypertensives with uncontrolled blood pressure (BP) levels. Fifty four subjects with moderate HT treated with one or two antihypertensive drugs were recruited and 50 entered two double blind cross-over treatment periods of 6 weeks each, with standardized tomato extract or identical placebo. Plasma concentrations of lycopene, nitrite and nitrate were measured and correlated with BP changes. There was a significant reduction of systolic BP after 6 weeks of tomato extract supplementation, from 145.8 ± 8.7 to 132.2 ± 8.6 mmHg (p < 0.001) and 140.4 ± 13.3 to 128.7 ± 10.4 mmHg (p < 0.001) in the two groups accordingly. Similarly, there was a decline in diastolic BP from 82.1 ± 7.2 to 77.9 ± 6.8 mmHg (p = 0.001) and from 80.1 ± 7.9 to 74.2 ± 8.5 mmHg (p = 0.001). There was no significant change in systolic and diastolic BP during the placebo period. Serum lycopene level increased from 0.11 ± 0.09 at baseline, to 0.30 ± 01.3 μmol/L after tomato extract therapy (p < 0.001). There was a significant correlation between systolic BP and lycopene levels (r = −0.49, p < 0.001). Tomato extract when added to patients treated with low doses of ACE inhibition, calcium channel blockers or their combination with low dose diuretics, had a clinically significant effect—reduction of BP by more than 10 mmHg systolic and more than 5 mmHg diastolic pressure. No side-effects to treatment were recorded and the compliance with treatment was high. The significant correlation between systolic blood pressure values and level of lycopene suggest the possibility of cause–effect relationships.


  • Blood Pressure Treatment and Cognition in the Elderly

    by Esther Paran, Ofra Anson

    While the health and longevity benefits of antihypertensive treatment have been established in past research, the cognitive consequences of blood pressure control in the elderly are still under debate. In this paper, the authors review the current evidence and the different ways in which cognition is measured. Since research on the cognitive consequences of blood pressure control in the elderly population is characterized by a variety of research questions, designs, and cognitive measurements, the authors conclude that a large‐scale study that compares the cognitive benefits of different methods of blood pressure reduction is urgently needed.


    • 26 July 2005
      • Vol. 12  (4) , 359-65

    Hypertension and cognitive functioning among the elderly: an overview.

    by Ofra Anson, Esther Paran

    This paper reviews the longitudinal studies in which the association between hypertension and cognitive functioning has been explored. The findings of these studies are far from being consistent: positive, adverse, or no relationships between cognitive performance and blood pressure have been reported. In some studies, cognitive functioning was related only to systolic blood pressure, whereas in others, it was related to diastolic blood pressure alone. Most probably, the inconsistency is due to the variability in research design, the measures employed, and data management. Some of the main methodological issues are the wide range in the age of the subjects and the variability in hypertension at baseline. Length of exposure to hypertension was rarely considered, and the search for the possible effects of the different antihypertensive treatments on cognitive ability is in its infancy. Many studies seek to identify cognitively impaired elderly and do not distinguish between the different types of dementia or the different cognitive domains. Thus, the possibility that hypertension affects specific cognitive functions has not been explored. The use of subdivisions of blood pressure values may have obscured nonlinear relationship. Nevertheless, the pattern that emerges is that midlife hypertension enhances cognitive impairment later in life, but at old age, mild hypertension may increase cognitive performance. Directions for future research to further elucidate the complex relationship between age, blood pressure, and cognition are discussed.